Drug Profile
PBD 2131
Alternative Names: HemoMexI; HemoMexS; PAM-200; Pandimex; PBD-1226; PBD2131Latest Information Update: 11 Mar 2015
Price :
$50
*
At a glance
- Originator Panagin Pharmaceuticals
- Class Antineoplastics; Phytotherapies
- Mechanism of Action Apoptosis stimulants; Caspase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Neutropenia; Solid tumours
Most Recent Events
- 11 Mar 2015 No recent reports on development identified - Registered for Cancer and Neutropenia in Georgia (PO)
- 11 Mar 2015 No recent reports on development identified - Registered for Solid tumours and Neutropenia in Georgia and Uzbekistan (IV)
- 20 Feb 2004 Preclinical trials in Cancer in Canada (unspecified route)